ClinicalTrials.gg
Active, not recruitingNCT02645487SRSUpdated Oct 7, 2026Results posted

Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis

An interventional study of Stereotactic Radiosurgery in Brain Neoplasms, Adult, Malignant, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
168th of 1,192
105 · median 30
Started
2015
with 57 others
No phase
226 of 1,447
64 open now
Primary completion
2025-03
later than 18 of 353 live
Registered
876th of 1,447
by date

Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 168th largest by enrollment of the 1,192 interventional ones that give a count, is one of 58 that started in 2015, is one of 226 with no phase, reaches primary completion later than 18 of the 353 other live ones, and was the 876th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

228 more — sign in →

All 233 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,447 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses. This may lead to an improvement in local control, patient survival, and/or quality-of life.

Read the detailed description

Recently, several large randomized studies have shown that in patients with limited brain metastases, whole brain radiation can be safely deferred when treated with SRS and close surveillance. In light of this, most of such patients are now treated with SRS alone without WBRT. However, the SRS doses set by Radiation Therapy Oncology Group (RTOG) 90-05 continue to be applied to patients without previous cranial irradiation.

The potential insufficiency of current SRS dose for long-term tumor control is of pressing concern. The advances chemotherapy has led to an improvement in overall survival in many patients with metastatic cancer, including malignancies often associated with brain metastases, such as lung (40-50%) and breast (15%). As these patients survive longer, more patients may develop brain metastases and the current dose of SRS may not be adequate to control the brain metastases for the duration of their survival. In fact, there is evidence that the control rate declines with time after SRS, and after 3 years, the local control rate may be only about 60%. In the case of brain metastases from relatively radio-resistant melanoma, the reported 12-months local control rates for SRS range from 52% to 75%. More potent SRS doses could lead to improved long-term control of brain metastases.

03

Conditions studied

  • Brain Neoplasms, Adult, Malignant

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -proven non-hematopoietic , except for small cell lung cancer, germ cell cancer, or unknown primary tumor.
  2. Radiographic evidence by MRI (or by CT scan with CT contrast if ineligible or intolerant of MRI) of . (If patient is unable to tolerate MRI contrast, an MRI without contrast is acceptable if lesions are visible)
  3. All brain metastases must be outside the brain stem (midbrain, pons and medulla).
  4. Patient must have 10 or less brain metastases.
  5. The maximum diameter of any lesion must be less than or equal to 3.0 cm.
  6. Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed provided that:

    • Radiation was not to the brain.
    • Surgery to the brain was > 7 days prior to SRS and there remains at least one additional brain metastasis that can be targeted with SRS
  7. Age ≥ 18 years.
  8. Performance Score of 2 or better/ Performance Status score of 50-60 or better.
  9. All men, as well as women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  10. Ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria

  1. Patients had craniotomy and surgery to the brain within 7 days from the date of SRS.
  2. Patients with .

    NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive CSF cytology and/or equivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion.

  3. Patients with a to both MRI (with or without contrast) and CT scan (with contrast)
  4. Patients with \< 3 months.
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
  6. Subjects must not be pregnant or nursing at the time of SRS treatment due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Stereotactic Radiosurgery

    Radiation, Stereotactic Radiosurgery Dose-Escalation

    Radiation: Stereotactic Radiosurgery

Interventions

  • RadiationStereotactic Radiosurgery

    Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy

    Also known as: SRS

06

What researchers measure

Primary outcomes

  1. Maximal Tolerated Doses

    The maximal tolerated doses for single-fraction stereotactic radiosurgery, within 90 days from the date of procedure, in patients with brain metastases who have not undergone prior brain irradiation was determined according to the following conditions: if zero or one out of the first seven, two or fewer out of the first nine, three or fewer out of the first twelve, or four or fewer out of the first fifteen of patients within 3-month follow-up experience a dose-limiting toxicity (DLT) as defined in the study protocol, then the dose was escalated to the next dose level according to principal investigator discretion. If three or more of the first nine patients, four or more of the first twelve, or five or more of the first fifteen patients experienced a DLT, then the maximum tolerated dose (MTD) was considered to have been exceeded. Each cohort had 3 maximum dose levels that could be met by reaching the dose escalation conditions.

    Time frame: 90 days

Secondary outcomes

  1. Overall Survival

    To evaluate the overall survival (OS), which is defined as the time between date of SRS and the date of death due to any cause.

    Time frame: 3 years

  2. Time to Progression

    To evaluate time to progression (TTP), which is defined as the time between date of SRS and date of documented progression. Specific TTP will be determined for the target lesion, non-target lesions, and elsewhere in brain.

    Time frame: 3 years

  3. Local Progression Rate

    To evaluate the local progression rate of the target lesion. Local progression will be defined by MRI (with or without contrast)/CT (with contrast) imaging according to the modified RECIST 1.1 criteria. Suspected radiation necrosis and/or pseudoprogression will be similarly evaluated

    Time frame: 3 years

  4. Response Rate

    To evaluate the response rate, consisting of complete response (CR) and partial response according to the modified RECIST 1.1.

    Time frame: 3 years

07

Results

Posted Oct 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1
Started16128151491777
Completed treatment13127141491377
Completed641663602
Not completed10879861175
Withdrew: Death733862645
Withdrew: Screen failure311100400
Withdrew: Physician decision031023130
Withdrew: Lost to follow-up011000000
Withdrew: Active follow up001001000

Outcome measures

PrimaryMaximal Tolerated Doses

The maximal tolerated doses for single-fraction stereotactic radiosurgery, within 90 days from the date of procedure, in patients with brain metastases who have not undergone prior brain irradiation was determined according to the following conditions: if zero or one out of the first seven, two or fewer out of the first nine, three or fewer out of the first twelve, or four or fewer out of the first fifteen of patients within 3-month follow-up experience a dose-limiting toxicity (DLT) as defined in the study protocol, then the dose was escalated to the next dose level according to principal investigator discretion. If three or more of the first nine patients, four or more of the first twelve, or five or more of the first fifteen patients experienced a DLT, then the maximum tolerated dose (MTD) was considered to have been exceeded. Each cohort had 3 maximum dose levels that could be met by reaching the dose escalation conditions.

Time frame:
90 days
Reported as:
Number · gray
Maximal Tolerated Doses
grayCohort 1Cohort 2Cohort 3Cohort 4
Maximal Tolerated Doses30272115
SecondaryOverall Survival

To evaluate the overall survival (OS), which is defined as the time between date of SRS and the date of death due to any cause.

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryTime to Progression

To evaluate time to progression (TTP), which is defined as the time between date of SRS and date of documented progression. Specific TTP will be determined for the target lesion, non-target lesions, and elsewhere in brain.

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryLocal Progression Rate

To evaluate the local progression rate of the target lesion. Local progression will be defined by MRI (with or without contrast)/CT (with contrast) imaging according to the modified RECIST 1.1 criteria. Suspected radiation necrosis and/or pseudoprogression will be similarly evaluated

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryResponse Rate

To evaluate the response rate, consisting of complete response (CR) and partial response according to the modified RECIST 1.1.

Time frame:
3 years

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected at baseline pre-treatment and every 3 months after the completion of treatment, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Dose Level 17/13 (53.8%)2/13 (15.4%)13/13 (100%)
Cohort 1 Dose Level 23/12 (25%)6/12 (50%)12/12 (100%)
Cohort 1 Dose Level 33/7 (42.9%)1/7 (14.3%)7/7 (100%)
Cohort 2 Dose Level 18/14 (57.1%)1/14 (7.1%)13/14 (92.9%)
Cohort 2 Dose Level 26/14 (42.9%)7/14 (50%)14/14 (100%)
Cohort 2 Dose Level 32/9 (22.2%)6/9 (66.7%)9/9 (100%)
Cohort 3 Dose Level 18/13 (61.5%)6/13 (46.2%)12/13 (92.3%)
Cohort 3 Dose Level 25/7 (71.4%)3/7 (42.9%)7/7 (100%)
Cohort 4 Dose Level 15/7 (71.4%)4/7 (57.1%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventCohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1
AnemiaBlood and lymphatic system disorders0/130/120/70/140/142/90/131/70/7
SepsisInfections and infestations0/132/121/70/140/142/90/131/70/7
Intracranial hemorrhageNervous system disorders0/132/120/70/140/141/90/130/70/7
DysphagiaGastrointestinal disorders0/130/120/70/140/140/92/130/70/7
DyspneaRespiratory, thoracic and mediastinal disorders1/130/120/70/141/140/92/130/71/7
Lung infectionInfections and infestations1/131/120/70/141/141/92/130/70/7
Respiratory failureRespiratory, thoracic and mediastinal disorders2/130/121/70/140/141/90/130/70/7
Abdominal painGastrointestinal disorders0/130/121/70/142/140/90/130/71/7
Acute kidney injuryRenal and urinary disorders0/130/120/70/140/141/90/131/70/7
AnorexiaMetabolism and nutrition disorders0/130/120/70/140/140/90/130/71/7
Most frequent other events
Showing 10 of 140
Most frequent other events
EventCohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1
HypertensionVascular disorders9/139/125/79/1414/149/98/137/75/7
FatigueGeneral disorders10/139/125/713/1411/147/99/134/74/7
DyspneaRespiratory, thoracic and mediastinal disorders12/136/124/78/147/145/97/133/73/7
AnxietyPsychiatric disorders4/136/125/79/145/145/98/136/72/7
HeadacheNervous system disorders7/138/126/78/148/145/97/133/73/7
NauseaGastrointestinal disorders6/1310/123/79/1411/145/94/131/73/7
DizzinessNervous system disorders6/136/123/79/148/143/910/134/72/7
ArthralgiaMusculoskeletal and connective tissue disorders5/139/122/73/148/144/91/131/74/7
AnemiaBlood and lymphatic system disorders4/132/125/75/141/145/91/132/71/7
ConstipationGastrointestinal disorders7/137/124/710/149/144/96/132/72/7

Baseline characteristics

Patients within each cohort and dose level that completed treatment.

Age, Categorical
Age, Categorical(Participants)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
<=18 years0000000000
Between 18 and 65 years1083129663663
>=65 years34425374133
Age, Continuous
Age, Continuous(years)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
Mean60.5 (44 to 75)59.8 (35 to 80)62.1 (32 to 80)57.9 (32 to 78)58.3 (36 to 75)58.6 (42 to 73)67.3 (49 to 90)66.7 (59 to 75)59.4 (49 to 79)60.9 (32 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
Female66377256143
Male76477781653
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
Hispanic or Latino02302301011
Not Hispanic or Latino1310414126136684
Unknown or Not Reported0000000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
American Indian or Alaska Native0000000000
Asian0100000001
Native Hawaiian or Other Pacific Islander0000000000
Black or African American11232103316
White129511118134477
More than one race0000000000
Unknown or Not Reported0100100002
Region of Enrollment
Region of Enrollment(participants)Cohort 1 Dose Level 1Cohort 1 Dose Level 2Cohort 1 Dose Level 3Cohort 2 Dose Level 1Cohort 2 Dose Level 2Cohort 2 Dose Level 3Cohort 3 Dose Level 1Cohort 3 Dose Level 2Cohort 4 Dose Level 1Total
United States1312714149137796
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Mar 2025, 111 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's 111 months is above that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2015
First posted
Jan 1, 2016
StartActual
Dec 18, 2015
Primary completionActual
Mar 23, 2025
CompletionEst.
Dec 23, 2026
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Enrollment
135 (estimated)→105 (actual)
Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMaximal tolerated dosesTolerated DosesTime frame: 90 days
Oct 7, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: 3 years
  • EditedTime to progressionProgressionTime frame: 3 years
  • EditedLocal progression rateProgression RateTime frame: 3 years
  • EditedResponse rateRateTime frame: 3 years
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Enrollment 135 (estimated)→105 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMaximal tolerated dosesTolerated DosesTime frame: 90 days
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: 3 years
    • EditedTime to progressionProgressionTime frame: 3 years
    • EditedLocal progression rateProgression RateTime frame: 3 years
    • EditedResponse rateRateTime frame: 3 years
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02645487
Responsible party
Robert Timmerman (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jan 1, 2016
Start date
Dec 18, 2015
Primary completion
Mar 23, 2025
Completion
Dec 23, 2026 (estimated)
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Robert Timmerman, MD
principal investigator · UTSW

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion